Simon Moroney
Chairman chez BIOTALYS NV
Fortune : 581 789 $ au 30/04/2024
Postes actifs de Simon Moroney
Sociétés | Poste | Début | Fin |
---|---|---|---|
NOVARTIS AG | Director/Board Member | 28/02/2020 | - |
Independent Dir/Board Member | 28/02/2020 | - | |
BIOTALYS NV | Chairman | 01/04/2021 | - |
Historique de carrière de Simon Moroney
Anciens postes connus de Simon Moroney
Sociétés | Poste | Début | Fin |
---|---|---|---|
MORPHOSYS AG | Chief Executive Officer | 01/01/1992 | 01/09/2019 |
Founder | 01/01/1992 | 01/09/2019 | |
ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Director/Board Member | - | 17/02/2014 |
University of Cambridge | Corporate Officer/Principal | 01/01/1991 | 01/01/1992 |
Swiss Federal Institute of Technology | Corporate Officer/Principal | 01/01/1986 | 01/01/1989 |
Harvard Medical School | Corporate Officer/Principal | 01/01/1984 | 01/01/1986 |
Government of Germany | President | - | - |
University of British Columbia | Corporate Officer/Principal | - | - |
Formation de Simon Moroney
University of Oxford | Doctorate Degree |
Waikato University | Graduate Degree |
Statistiques
Internationale
Allemagne | 4 |
Royaume-Uni | 3 |
Suisse | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Sectorielle
Consumer Services | 7 |
Health Technology | 4 |
Government | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
NOVARTIS AG | Health Technology |
MORPHOSYS AG | Health Technology |
BIOTALYS NV | Process Industries |
Entreprise privées | 2 |
---|---|
Government of Germany | Government |
ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
- Bourse
- Insiders
- Simon Moroney
- Expérience